Direct oral anticoagulant administration in cirrhotic patients with portal vein thrombosis: What is the evidence?

Table 2 Efficacy of direct oral anticoagulants in portal vein thrombosis treatment in cirrhosis

Ref.	Study design	Drug administrated (n of patients)	Duration of treatment	PVT type	Results (cases vs controls)
Ai et al[87]	Prospective cohort study	Rivaroxaban 20 mg once daily (26 pts)	6 mo	Chronic PVT;	At 3 mo:; Complete/partial recanalization: 5 vs 0 (P = 0.026); At 6 mo:; Complete/partial recanalization: 11 vs 1 (P = 0.003)
		Dabigatran 150 mg twice daily (14 pts)	6 mo
		No treatment (40 pts)
Hanafy et al[88]	Randomized, controlled, interventional, open-label study	Rivaroxaban 10 mg twice daily (40 pts)	Until recanalization and prolonged for 1 or 2 mo in complete recanalization of PVT which non-involvement/ involvement of SMV and for 6 mo in case of positive thrombogenic assay or partial recanalization;	Acute PVT	Complete recanalization: 34 vs 18 (P = 0.001); Partial recanalization: 6 vs 0 (P = 0.001)
		Warfarin (40 pts)
Nagaoki et al[86]	Retrospective cohort study	Edoxaban 60 mg or 30 mg once daily (20 pts)	6 mo	PVT	Complete recanalization: 14 vs 6 (P < 0.001); Partial recanalization: 4 vs 3 (P = 0.312)
		Warfarin (30 pts)

PVT: Portal vein thrombosis.